FindTrial
Sign In

A Prospective Study to Assess the Screening Value of N-terminal Pro-B-type Natriuretic Peptide (NT-proBNP) for the Identification of Patients That Benefit From Additional Cardiac Testing Prior to Vascular Surgery

A Prospective Study to Assess the Screening Value of N-terminal Pro-B-type Natriuretic Peptide (NT-proBNP) for the Identification of Patients That Benefit From Additional Cardiac Testing Prior to Vascular Surgery

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00519961
Enrollment
1800
Registered
2007-08-23
Start date
2007-02-28
Completion date
2010-09-30
Last updated
2011-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peripheral Vascular Disease

Brief summary

The purpose of this study is to validate the screening potential of NT-proBNP for the identification of patients scheduled for vascular surgery who would benefit from additional pre-operative cardiac testing. All patients will have NT-proBNP concentrations measured pre-operatively. For low-intermediate risk patients only those with abnormal values will receive further cardiac testing; all high risk patients will be referred for additional testing.

Interventions

DEVICEElecsys®proBNP

Sponsors

Hoffmann-La Roche
Lead SponsorINDUSTRY

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adult patients, ≥18 years of age * Patients with peripheral vascular atherosclerosis, scheduled for vascular surgery

Exclusion criteria

* N/A

Design outcomes

Primary

MeasureTime frame
Collection of 30-day and 1-year postoperative cardiac events30-day and 1-year postoperation

Countries

Ireland, Netherlands

Contacts

Primary ContactRoche Diagnostics Center
Dia_StudyInquiries@Roche.com1-866-805-5919 (U.S. Only)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026